Shattuck Labs Q3 net loss narrows to $10.1 mln

Shattuck Labs

06/11/2025 22:23

Overview

Shattuck Labs Q3 net loss narrows to $10.1 mln from $16.6 mln year-over-year

Company closed $103 mln private placement to fund SL-325 development

R&D expenses fell to $7.6 mln from $16.3 mln year-over-year

Outlook

Shattuck expects cash reserves to fund operations into 2029

Result Drivers

PRIVATE PLACEMENT - Closed $103 mln private placement to advance SL-325 into Phase 2 trials

R&D EXPENSES - R&D expenses fell to $7.6 mln from $16.3 mln year-over-year, reflecting focused investment in SL-325

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$10.06 mln
Q3 Basic EPS
-$0.14
Q3 Income From Operations
-$10.72 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Shattuck Labs Inc is $2.00, about 2% below its November 5 closing price of $2.04

Press Release: ID:nGNX1Mb6tC

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)